Maravai LifeSciences (MRVI) Expected to Announce Quarterly Earnings on Monday

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) is expected to be releasing its Q1 2025 earnings data after the market closes on Monday, May 12th. Analysts expect Maravai LifeSciences to post earnings of ($0.07) per share and revenue of $44.01 million for the quarter.

Maravai LifeSciences Trading Down 3.9 %

Maravai LifeSciences stock traded down $0.08 during mid-day trading on Friday, hitting $1.99. 2,210,332 shares of the stock were exchanged, compared to its average volume of 2,338,706. The stock has a market capitalization of $506.13 million, a price-to-earnings ratio of -1.21 and a beta of 0.19. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. Maravai LifeSciences has a 12 month low of $1.67 and a 12 month high of $11.56. The firm's fifty day simple moving average is $2.17 and its two-hundred day simple moving average is $4.23.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Baird R W cut Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. UBS Group cut their target price on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Stifel Nicolaus set a $5.00 price target on shares of Maravai LifeSciences in a report on Friday, March 21st. Morgan Stanley dropped their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Tuesday, March 25th. Finally, Robert W. Baird cut shares of Maravai LifeSciences from an "outperform" rating to a "neutral" rating and cut their price objective for the stock from $9.00 to $3.00 in a research report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, Maravai LifeSciences presently has an average rating of "Hold" and an average price target of $6.34.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.